

James B Bussel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3776884/publications.pdf>

Version: 2024-02-01

346
papers

24,936
citations

8159

76
h-index

7718

150
g-index

363
all docs

363
docs citations

363
times ranked

10245
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal study of 2 patients with cyclic thrombocytopenia, <i>STAT3</i> and <i>MPL</i> mutations. <i>Blood Advances</i> , 2023, 7, 190-194.	2.5	5
2	Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: <i>postâ€hoc</i> analysis of the EXTEND study. <i>British Journal of Haematology</i> , 2022, 196, 448-452.	1.2	0
3	SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. <i>Blood</i> , 2022, 139, 1564-1574.	0.6	55
4	Disorders of platelets. , 2022, , 237-285.		0
5	Hemolysis after highâ€dose intravenous immunoglobulin: An underâ€appreciated sequelae. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
6	Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag inâ€vitro. <i>Blood Advances</i> , 2022, 6, 13-27.	2.5	2
7	A Single-Arm, Long-Term Efficacy and Safety Study of Subcutaneous Romiplostim in Children with Immune Thrombocytopenia. <i>Blood Advances</i> , 2022, , .	2.5	1
8	Immune thrombocytopenia (ITP) World Impact Survey (iWISH): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. <i>American Journal of Hematology</i> , 2021, 96, 188-198.	2.0	55
9	Immune thrombocytopenia (<sc>ITP</sc>) <sc>World Impact Survey</sc> (<sc>Iâ€WISH</sc>): Impact of <sc>ITP</sc> on healthâ€related quality of life. <i>American Journal of Hematology</i> , 2021, 96, 199-207.	2.0	54
10	Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110108.	1.1	26
11	Fetal and Neonatal Alloimmune Thrombocytopenias. , 2021, , 223-242.		0
12	Thrombocytopenia following Pfizer and Moderna <sc>SARSâ€CoV</sc>â€2 vaccination. <i>American Journal of Hematology</i> , 2021, 96, 534-537.	2.0	331
13	Quality of life is an important indication for secondâ€line treatment in children with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29023.	0.8	4
14	Immune thrombocytopenia during the COVIDâ€19 pandemic. <i>British Journal of Haematology</i> , 2021, 193, 1093-1095.	1.2	6
15	A Review of Romiplostim Mechanism of Action and Clinical Applicability. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2243-2268.	2.0	35
16	Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients. <i>ELife</i> , 2021, 10, .	2.8	10
17	SARS-CoV-2 Vaccineâ€Induced Immune Thrombotic Thrombocytopenia. <i>New England Journal of Medicine</i> , 2021, 384, 2254-2256.	13.9	412
18	COVID-19 vaccination and immune thrombocytopenia. <i>Nature Medicine</i> , 2021, 27, 1145-1146.	15.2	29

#	ARTICLE	IF	CITATIONS
19	Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists. American Journal of Hematology, 2021, 96, E373-E376.	2.0	6
20	New developments in fetal and neonatal alloimmune thrombocytopenia. American Journal of Obstetrics and Gynecology, 2021, 225, 120-127.	0.7	33
21	Familial thrombocythaemia â€“ a distinct entity from essential thrombocythaemia. British Journal of Haematology, 2021, 194, 808-809.	1.2	1
22	Heritable platelet disorders: an enigma even guidelines canâ€™t unravel. British Journal of Haematology, 2021, 195, 13-14.	1.2	0
23	Immune thrombocytopenia. Expert Review of Hematology, 2021, 14, 1013-1025.	1.0	12
24	Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study). Blood, 2021, 138, 2088-2088.	0.6	3
25	Surveillance Program of Romiplostim Use Connected to Pregnancy. Blood, 2021, 138, 585-585.	0.6	2
26	Do Splenectomized Immune Thrombocytopenia (ITP) Patients Have Increased Risks for Platelet Decreases Following COVID-19 Vaccination?. Blood, 2021, 138, 2090-2090.	0.6	0
27	Splenectomy Results in Venous Thromboembolic Events in Women: A Nurses Health Study. Blood, 2021, 138, 3163-3163.	0.6	1
28	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. Blood, 2021, 138, 586-586.	0.6	1
29	LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia. Blood, 2021, 138, 1010-1010.	0.6	5
30	COVID-19 Vaccination in Adults with Immune Thrombocytopenia (ITP): Data from the Platelet Disorder Support Association (PDSA) Patient Registry. Blood, 2021, 138, 3164-3164.	0.6	1
31	Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists. Platelets, 2020, 31, 198-205.	1.1	19
32	Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists. Platelets, 2020, 31, 322-328.	1.1	6
33	Immune Thrombocytopenia: A Complex Autoimmune Disease. , 2020, , 911-921.		1
34	Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP). British Journal of Haematology, 2020, 189, 379-382.	1.2	4
35	Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists. Thrombosis Research, 2020, 185, 119-124.	0.8	20
36	Early combination treatment of immune thrombocytopenia: Is this the way?. American Journal of Hematology, 2020, 95, 1452-1453.	2.0	0

#	ARTICLE	IF	CITATIONS
37	Identification of occult cerebral microbleeds in adults with immune thrombocytopenia. <i>Blood</i> , 2020, 136, 2875-2880.	0.6	9
38	Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome. <i>Blood Advances</i> , 2020, 4, 3368-3377.	2.5	11
39	Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 190, 933-938.	1.2	38
40	Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 4136-4146.	2.5	60
41	Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 467-478.	1.5	66
42	Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. <i>Blood</i> , 2020, 136, 3056-3061.	0.6	42
43	Preparing patients with immune thrombocytopenia for surgery: what are the options?. <i>Lancet Haematology</i> , 2020, 7, e626-e627.	2.2	2
44	Fatigue in children and adolescents with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 191, 98-106.	1.2	18
45	Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children. <i>British Journal of Haematology</i> , 2020, 189, e37-e40.	1.2	13
46	Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102712.	0.5	14
47	Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. <i>Haematologica</i> , 2020, 105, e129-e132.	1.7	11
48	Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. <i>Blood</i> , 2020, 135, 472-490.	0.6	102
49	ITP World Impact Survey (I-WISH) 2.0: Further Exploration of the Impact of ITP on Patients. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
50	Clinical Outcomes in Patients with Immune Thrombocytopenia Treated with All 3 Approved Thrombopoietin Receptor Agonists. <i>Blood</i> , 2020, 136, 18-19.	0.6	0
51	Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2^{V617F}-positive myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2019, 185, 136-139.	1.2	14
52	Peri- and Postpartum Management of Patients With Factor XI Deficiency. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988026.	0.7	8
53	Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. <i>Seminars in Hematology</i> , 2019, 56, 262-278.	1.8	25
54	Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?. <i>Haematologica</i> , 2019, 104, 1124-1135.	1.7	58

#	ARTICLE	IF	CITATIONS
55	<i>FAS</i> mutations are an uncommon cause of immune thrombocytopenia in children and adults without additional features of immunodeficiency. <i>British Journal of Haematology</i> , 2019, 186, e163-e165.	1.2	6
56	Maternal sensitization occurs before delivery in severe cases of fetal alloimmune thrombocytopenia. <i>American Journal of Hematology</i> , 2019, 94, E213-E215.	2.0	5
57	Thrombopoietin receptor agonists: ten years later. <i>Haematologica</i> , 2019, 104, 1112-1123.	1.7	219
58	Response to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia. <i>American Journal of Hematology</i> , 2019, 94, E196-E198.	2.0	3
59	Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. <i>British Journal of Haematology</i> , 2019, 185, 549-562.	1.2	61
60	Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. <i>Haematologica</i> , 2019, 104, 2283-2291.	1.7	27
61	Immune Thrombocytopenia (ITP)., 2019, , 707-724.		3
62	Postnatal intervention for the treatment of FNAIT: a systematic review. <i>Journal of Perinatology</i> , 2019, 39, 1329-1339.	0.9	23
63	Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. <i>American Journal of Hematology</i> , 2019, 94, 741-750.	2.0	37
64	Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. <i>American Journal of Hematology</i> , 2019, 94, 546-553.	2.0	67
65	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3780-3817.	2.5	593
66	Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, e257-e259.	0.3	4
67	Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. <i>British Journal of Haematology</i> , 2019, 185, 102-106.	1.2	15
68	Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. <i>Vox Sanguinis</i> , 2019, 114, 79-94.	0.7	33
69	Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study. <i>American Journal of Hematology</i> , 2019, 94, 200-208.	2.0	22
70	Platelet transfusion practices in immune thrombocytopenia related hospitalizations. <i>Transfusion</i> , 2019, 59, 169-176.	0.8	23
71	Fetal and Neonatal Alloimmune Thrombocytopenia. , 2019, , 581-588.		1
72	Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. <i>Platelets</i> , 2019, 30, 206-212.	1.1	21

#	ARTICLE	IF	CITATIONS
73	Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment. <i>Platelets</i> , 2019, 30, 222-228.	1.1	1
74	Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study. <i>Blood</i> , 2019, 134, 1081-1081.	0.6	1
75	Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics. <i>Blood</i> , 2019, 134, 1090-1090.	0.6	11
76	Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients. <i>Blood</i> , 2019, 134, 1069-1069.	0.6	2
77	Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia. <i>Blood</i> , 2019, 134, 4889-4889.	0.6	4
78	Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia. <i>Blood</i> , 2019, 134, 897-897.	0.6	5
79	Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2019, 134, 1095-1095.	0.6	6
80	The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey. <i>Blood</i> , 2019, 134, 1076-1076.	0.6	3
81	Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?. <i>Clinical Hematology International</i> , 2019, 1, 173-179.	0.7	0
82	Physicians' and Patients' Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISH). <i>Blood</i> , 2019, 134, 1097-1097.	0.6	1
83	Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry. <i>Blood</i> , 2019, 134, 2362-2362.	0.6	4
84	Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. <i>American Journal of Hematology</i> , 2018, 93, 882-888.	2.0	30
85	Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. <i>American Journal of Hematology</i> , 2018, 93, 921-930.	2.0	215
86	Fostamatinib for persistent/chronic adult immune thrombocytopenia. <i>Immunotherapy</i> , 2018, 10, 9-25.	1.0	53
87	Health-related quality of life in adult primary immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2018, 11, 975-985.	1.0	22
88	Avatrombopag. <i>British Journal of Haematology</i> , 2018, 183, 342-343.	1.2	5
89	TPO-mimetics for chemotherapy-induced thrombocytopenia: timing matters. <i>Leukemia and Lymphoma</i> , 2018, 59, 2763-2764.	0.6	2
90	Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	48

#	ARTICLE	IF	CITATIONS
91	IVIg and Fc γ R1b in kids with ITP: individualizing therapy. <i>Blood</i> , 2018, 132, 877-878.	0.6	2
92	Screening for Wiskott-Aldrich syndrome by flow cytometry. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 333-335.e8.	1.5	20
93	Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. <i>Rheumatology</i> , 2018, 57, 1432-1438.	0.9	38
94	Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim. <i>Blood</i> , 2018, 132, 735-735.	0.6	11
95	Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-WISH). <i>Blood</i> , 2018, 132, 2273-2273.	0.6	14
96	Results from the ITP World IMPACT Survey (I-WISH): Patients with Immune Thrombocytopenia (ITP) Experience Impaired Quality of Life (QoL) Regarding Daily Activities, Social Interactions, Emotional Well-Being and Working Lives. <i>Blood</i> , 2018, 132, 4804-4804.	0.6	4
97	Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials. <i>Blood</i> , 2018, 132, 3740-3740.	0.6	1
98	Two placebo-controlled phase 3 studies of fostamatinib, an oral spleen tyrosine kinase (Syk) inhibitor, for the treatment of persistent/chronic immune thrombocytopenia (ITP) in adults: Analysis of platelet response by prior ITP therapies.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15146-e15146.	0.8	0
99	Thrombin-Generating Capacity of Microvesicles (MVs) in Patients with Immune Thrombocytopenia (ITP) before and during Treatment with Thrombopoietin-Receptor Agonists (TPO-RA). <i>Blood</i> , 2018, 132, 2511-2511.	0.6	0
100	Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study. <i>Blood</i> , 2018, 132, 1152-1152.	0.6	0
101	Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding. <i>Blood</i> , 2018, 132, 4717-4717.	0.6	1
102	Medical Decision Analysis: Choosing Second Line Treatment in Adults with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2018, 132, 4986-4986.	0.6	0
103	Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. <i>Blood</i> , 2017, 129, 1538-1547.	0.6	91
104	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. <i>Haematologica</i> , 2017, 102, 1192-1203.	1.7	92
105	Immune Thrombocytopenia: Where Are We Now?. , 2017, , 749-760.		0
106	Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2017, 92, 730-738.	2.0	49
107	Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. <i>Blood</i> , 2017, 130, 2527-2536.	0.6	228
108	TPO for ITP in pregnancy. <i>Blood</i> , 2017, 130, 1073-1074.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Imaging and management of fetuses and neonates with alloimmune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26690.	0.8	13
110	Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone. <i>Journal of Pediatrics</i> , 2017, 191, 225-231.	0.9	26
111	Immune thrombocytopenia: a need for assisted suicide. <i>British Journal of Haematology</i> , 2017, 176, 154-154.	1.2	1
112	Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP). <i>Platelets</i> , 2017, 28, 478-483.	1.1	10
113	Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP). <i>Blood</i> , 2017, 130, 752-752.	0.6	2
114	Disorders of Platelets. , 2016, , 239-278.		3
115	Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. <i>Haematologica</i> , 2016, 101, e237-e239.	1.7	17
116	Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. <i>Haematologica</i> , 2016, 101, 1327-1332.	1.7	9
117	Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 471.e1-471.e9.	0.7	16
118	Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. <i>Lancet, The</i> , 2016, 388, 45-54.	6.3	116
119	Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia. <i>Transfusion</i> , 2016, 56, 2449-2454.	0.8	6
120	Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor. <i>British Journal of Haematology</i> , 2016, 173, 942-945.	1.2	30
121	What do we know about intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia?. <i>Transfusion</i> , 2016, 56, 17-18.	0.8	1
122	Platelet count control in immune thrombocytopenic purpura patient: Optimum romiplostim dose profile. <i>Journal of Process Control</i> , 2016, 45, 76-83.	1.7	4
123	Gender and duration of disease differentiate responses to rituximab+dexamethasone therapy in adults with immune thrombocytopenia. <i>American Journal of Hematology</i> , 2016, 91, 907-911.	2.0	45
124	Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim. <i>Hematology</i> , 2016, 21, 257-262.	0.7	26
125	Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. <i>Platelets</i> , 2016, 27, 472-478.	1.1	14
126	Hepatobiliary and Thromboembolic Events during Long-Term E.X.T.E.N.Ded Treatment with Eltrombopag in Adult Patients with Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2016, 128, 1368-1368.	0.6	5

#	ARTICLE	IF	CITATIONS
127	Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study. <i>Blood</i> , 2016, 128, 3742-3742.	0.6	3
128	Efficacy of Eltrombopag in Adult East Asian and Non-East Asian Patients with Chronic Immune Thrombocytopenia (cITP): Results from the Extend Study. <i>Blood</i> , 2016, 128, 4930-4930.	0.6	4
129	Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). <i>Pediatric Blood and Cancer</i> , 2015, 62, 208-213.	0.8	60
130	Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. <i>Blood</i> , 2015, 126, 1367-1378.	0.6	82
131	Suppression of in vitro megakaryopoiesis by maternal sera containing anti-HPA-1a antibodies. <i>Blood</i> , 2015, 126, 1234-1236.	0.6	17
132	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. <i>PLoS Genetics</i> , 2015, 11, e1005262.	1.5	128
133	Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. <i>Lancet, The</i> , 2015, 386, 1649-1658.	6.3	164
134	Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. <i>Lancet Haematology, the</i> , 2015, 2, e315-e325.	2.2	146
135	Thrombopoietin Receptor Agonists: A Critical Review. <i>Seminars in Hematology</i> , 2015, 52, 46-52.	1.8	30
136	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. <i>Blood</i> , 2015, 126, 73-73.	0.6	6
137	Clinical Features of Alloimmune Neutropenia: Composite of 2 Case Series and 39 Case Reports. <i>Blood</i> , 2015, 126, 4607-4607.	0.6	0
138	Effects of Anti-Glycoprotein Antibodies on Response of Immune Thrombocytopenia Patients to Thrombopoietin Receptor Agonists and on Megakaryocytes Viability. <i>Blood</i> , 2015, 126, 1048-1048.	0.6	0
139	Standard Dose Rituximab and 3 4-Day Cycles of Dexamethasone (R+3D) Appears Curative in Females with ITP < 12 Months Duration. <i>Blood</i> , 2015, 126, 1059-1059.	0.6	1
140	Review of fetal and neonatal immune cytopenias. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 35-43.	0.3	18
141	Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. <i>American Journal of Hematology</i> , 2014, 89, E228-34.	2.0	31
142	The new thrombopoietic agenda: Impact on leukemias and MDS. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 288-292.	0.7	7
143	Management of thrombocytopenia. <i>F1000prime Reports</i> , 2014, 6, 45.	5.9	77
144	Thrombopoietic agents: There is still much to learn. <i>Presse Medicale</i> , 2014, 43, e69-e78.	0.8	15

#	ARTICLE	IF	CITATIONS
145	Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2014, 166, 592-600.	1.2	84
146	Thrombopoietic Agents for the Treatment of Persistent and Chronic Immune Thrombocytopenia in Children. <i>Journal of Pediatrics</i> , 2014, 165, 600-605.e4.	0.9	49
147	Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. <i>Haematologica</i> , 2014, 99, 1264-1271.	1.7	80
148	Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. <i>Haematologica</i> , 2014, 99, 937-944.	1.7	84
149	Platelet count control in immune thrombocytopenic purpura patient: optimum romiplostim dose profile. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2014, 47, 11800-11805.	0.4	2
150	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. <i>Blood</i> , 2014, 123, 3887-3894.	0.6	112
151	Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. <i>Blood</i> , 2014, 124, e4-e10.	0.6	112
152	IRAK-4 and MyD88 deficiencies impair IgM responses against T-independent bacterial antigens. <i>Blood</i> , 2014, 124, 3561-3571.	0.6	58
153	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. <i>Haematologica</i> , 2014, 99, 1387-1394.	1.7	63
154	PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2014, 124, 1450-1450.	0.6	7
155	Response to TPO-Receptor Agonists: Role of Immature Platelet Fraction and Anti-GP1b. <i>Blood</i> , 2014, 124, 4190-4190.	0.6	1
156	Thrombopoietin Receptor Agonists in Paediatric ITP Patients: Long Term Follow up Data in 34 Patients. <i>Blood</i> , 2014, 124, 4206-4206.	0.6	6
157	Safety and Efficacy of Long-Term Open-Label Dosing of Romiplostim in Thrombocytopenic Pediatric Patients (Pts) with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2014, 124, 4184-4184.	0.6	0
158	Classical Pathway of Complement Activation in ITP: Inhibition By TNT003, a Novel C1s Inhibitor. <i>Blood</i> , 2014, 124, 1453-1453.	0.6	2
159	Issues in Categorization and Management of Pediatric Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2014, 124, 1843-1843.	0.6	0
160	Enhanced Megakaryocyte Apoptosis Corresponds to Higher Platelet Counts in Immune Thrombocytopenia Patients and Increased Proplatelet Formation in Cell Culture. <i>Blood</i> , 2014, 124, 5114-5114.	0.6	0
161	Effects of Thrombopoietin Mimetics on Patients with Chronic ITP: Perspectives from Blood Transcriptome Profiling Analysis. <i>Blood</i> , 2014, 124, 2780-2780.	0.6	0
162	Low dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. <i>British Journal of Haematology</i> , 2013, 162, 693-701.	1.2	25

#	ARTICLE	IF	CITATIONS
163	Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). British Journal of Haematology, 2013, 160, 538-546.	1.2	58
164	The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (<scp>ITP</scp>). British Journal of Haematology, 2013, 160, 237-243.	1.2	22
165	Immune Thrombocytopenia (ITP)., 2013, , 819-833.		6
166	Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology, 2013, 161, 411-423.	1.2	234
167	Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, 2013, 121, 537-545.	0.6	295
168	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood, 2013, 121, 2596-2606.	0.6	179
169	Modified antibody in fetal alloimmunization. Blood, 2013, 122, 303-304.	0.6	2
170	Fetal and Neonatal Alloimmune Thrombocytopenia. , 2013, , 609-613.		1
171	Update On The Safety and Efficacy Of EXTENDED Treatment With Eltrombopag (EPAG) In Adults With Chronic Immune Thrombocytopenia (ITP). Blood, 2013, 122, 2315-2315.	0.6	5
172	Safety and Efficacy Of Eltrombopag At Escalated Doses Up To 150mg In Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive To 75 Mg. Blood, 2013, 122, 3559-3559.	0.6	3
173	Self-administration of romiplostim in patients with chronic immune thrombocytopenia. Community Oncology, 2013, 10, 285-292.	0.2	6
174	Cyclosporine-Romiplostim-IVIg Combination Therapy In Patients With Severe Immune Thrombocytopenia (ITP). Blood, 2013, 122, 1085-1085.	0.6	0
175	Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP). Blood, 2013, 122, 3530-3530.	0.6	0
176	Thrombopoietin-receptor agonists. Current Opinion in Hematology, 2012, 19, 392-398.	1.2	36
177	Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Modern Pathology, 2012, 25, 65-74.	2.9	37
178	Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood, 2012, 119, 5989-5995.	0.6	284
179	Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood, 2012, 120, 3318-3325.	0.6	164
180	Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. British Journal of Haematology, 2012, 158, 811-814.	1.2	24

#	ARTICLE	IF	CITATIONS
181	How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. <i>Blood</i> , 2012, 120, 960-969.	0.6	197
182	In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. <i>Blood</i> , 2012, 119, 4066-4072.	0.6	86
183	Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). <i>Pediatric Blood and Cancer</i> , 2012, 58, 395-398.	0.8	41
184	Successful Discontinuation of Eltrombopag Treatment in Patients with Chronic ITP. <i>Blood</i> , 2012, 120, 1085-1085.	0.6	19
185	Dynamics of Improvement in Health-Related Quality of Life (HRQoL) with Long-Term Eltrombopag Treatment in Adults with Chronic Immune Thrombocytopenia (ITP) in EXTEND.. <i>Blood</i> , 2012, 120, 2199-2199.	0.6	0
186	Survey of the Side Effects of ITP Therapies. <i>Blood</i> , 2012, 120, 3327-3327.	0.6	1
187	Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. <i>Lancet, The</i> , 2011, 377, 393-402.	6.3	480
188	Eltrombopag for chronic immune thrombocytopenia – Authors' reply. <i>Lancet, The</i> , 2011, 377, 1919-1920.	6.3	0
189	Fetal and Neonatal Alloimmune Thrombocytopenia. <i>Obstetrics and Gynecology</i> , 2011, 118, 1157-1163.	1.2	98
190	A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. <i>Blood</i> , 2011, 118, 28-36.	0.6	195
191	Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. <i>Blood</i> , 2011, 117, 5723-5732.	0.6	130
192	Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. <i>British Journal of Haematology</i> , 2011, 155, 248-255.	1.2	34
193	Standard Dose Rituximab Plus 2-4 Cycles of Pulse Dexamethasone Is Effective and Tolerable in Treatment of Immune Thrombocytopenia (ITP). <i>Blood</i> , 2011, 118, 1166-1166.	0.6	1
194	Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,. <i>Blood</i> , 2011, 118, 3281-3281.	0.6	9
195	Cumulative Response to Eltrombopag and Impact of the Number of Prior ITP Therapies: Interim Results of a Long-Term Extension Study,. <i>Blood</i> , 2011, 118, 3297-3297.	0.6	2
196	Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. <i>Blood</i> , 2010, 116, 4639-4645.	0.6	262
197	The Long-term Impact of Rituximab for Childhood Immune Thrombocytopenia. <i>Current Rheumatology Reports</i> , 2010, 12, 94-100.	2.1	26
198	Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 135.e1-135.e14.	0.7	81

#	ARTICLE	IF	CITATIONS
199	Stability of measurement of the immature platelet fraction. American Journal of Hematology, 2010, 85, 622-624.	2.0	24
200	International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010, 115, 168-186.	0.6	1,802
201	Thrombopoietic Agents in Immune Thrombocytopenia. Seminars in Hematology, 2010, 47, 258-265.	1.8	15
202	Eltrombopag. Cancer Treatment and Research, 2010, 157, 289-303.	0.2	11
203	Platelet Function and Response to Thrombopoietin Mimetics In Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.. Blood, 2010, 116, 1429-1429.	0.6	5
204	Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. Haematologica, 2010, 95, 1807-1811.	1.7	31
205	The Effect of Eltrombopag on Human Platelet Resistance to Apoptosis: The Role of the Bcl-XI Pathway. Blood, 2010, 116, 2520-2520.	0.6	0
206	The Use of Immature Platelet Fraction to Assess Thrombopoiesis and Mechanisms of Treatment Effect In Immune Thrombocytopenia (ITP). Blood, 2010, 116, 2513-2513.	0.6	7
207	Rituximab Maintenance Treatment In Immune Mediated Thrombocytopenia (ITP) Including Evans Syndrome. Blood, 2010, 116, 2523-2523.	0.6	0
208	Current Approaches to the Evaluation and Management of the Fetus and Neonate with Immune Thrombocytopenia. Seminars in Perinatology, 2009, 33, 35-42.	1.1	90
209	Repeated courses of rituximab in chronic ITP: Three different regimens. American Journal of Hematology, 2009, 84, 661-665.	2.0	71
210	One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatric Blood and Cancer, 2009, 52, 259-262.	0.8	51
211	Cytomegalovirus can make immune thrombocytopenic purpura refractory. British Journal of Haematology, 2009, 146, 104-112.	1.2	79
212	Traditional and New Approaches to the Management of Immune Thrombocytopenia: Issues of When and Who to Treat. Hematology/Oncology Clinics of North America, 2009, 23, 1329-1341.	0.9	5
213	The ITP syndrome: pathogenic and clinical diversity. Blood, 2009, 113, 6511-6521.	0.6	662
214	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113, 2386-2393.	0.6	2,128
215	The Changing Landscape of Secondary ITP: Introduction. Seminars in Hematology, 2009, 46, S1.	1.8	2
216	Therapeutic Approaches to Secondary Immune Thrombocytopenic Purpura. Seminars in Hematology, 2009, 46, S44-S58.	1.8	16

#	ARTICLE	IF	CITATIONS
217	Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2009, 373, 641-648.	6.3	493
218	Risk Factors for Thrombocytopenia in HIV-Infected Persons in the Era of Potent Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 52, 595-599.	0.9	35
219	Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. <i>Blood</i> , 2009, 113, 2161-2171.	0.6	406
220	Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. <i>Blood</i> , 2009, 113, 3154-3160.	0.6	229
221	Effects of eradication of <i>Helicobacter pylori</i> infection in patients with immune thrombocytopenic purpura: a systematic review. <i>Blood</i> , 2009, 113, 1231-1240.	0.6	273
222	Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. <i>Blood</i> , 2009, 114, 4777-4783.	0.6	184
223	Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2009, 114, 1322-1322.	0.6	3
224	3G8 and GMA161, Anti Fc γ RIII Inhibitory Monoclonal Antibodies in the Treatment of Chronic Refractory ITP. (Summary of 2 Pilot Studies).. <i>Blood</i> , 2009, 114, 2404-2404.	0.6	12
225	A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2009, 114, 680-680.	0.6	5
226	Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.. <i>Blood</i> , 2009, 114, 681-681.	0.6	4
227	Long-Term Treatment of Chronic Immune Thrombocytopenic Purpura with Oral Eltrombopag: Results From the EXTEND Study.. <i>Blood</i> , 2009, 114, 682-682.	0.6	6
228	Association Between IgA Immunoglobulin Level and Response to Treatment for Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2009, 114, 3503-3503.	0.6	0
229	Time to Splenectomy Failure in Patients with Recurrent or Refractory Chronic Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2009, 114, 3522-3522.	0.6	0
230	Update on eltrombopag for ITP. <i>Oncology</i> , 2009, 23, 1177-8.	0.4	10
231	Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2008, 83, 150-154.	2.0	142
232	Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. <i>Blood Reviews</i> , 2008, 22, 33-52.	2.8	78
233	Refractory immune thrombocytopenic purpura: current strategies for investigation and management. <i>British Journal of Haematology</i> , 2008, 143, 16-26.	1.2	72
234	Overview of Thrombopoietic Agents in the Treatment of Thrombocytopenia. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 33-43.	1.4	8

#	ARTICLE	IF	CITATIONS
235	Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. <i>Health and Quality of Life Outcomes</i> , 2008, 6, 13.	1.0	86
236	Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. <i>Blood</i> , 2008, 112, 1325-1328.	0.6	207
237	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. <i>Lancet, The</i> , 2008, 371, 395-403.	6.3	784
238	How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 424-425.	1.7	3
239	The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. <i>Current Opinion in Oncology</i> , 2008, 20, 690-696.	1.1	14
240	Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. <i>Current Opinion in Pediatrics</i> , 2008, 20, 8-16.	1.0	26
241	Fc receptors in immune thrombocytopenias: a target for immunomodulation?. <i>Journal of Clinical Investigation</i> , 2008, 118, 2677-81.	3.9	27
242	Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE). <i>Blood</i> , 2008, 112, 400-400.	0.6	24
243	Self-Injection of Romiplostim by Patients with Chronic Immune Thrombocytopenic Purpura (ITP). <i>Blood</i> , 2008, 112, 4707-4707.	0.6	1
244	Novel Thrombopoietic Agents. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 106-113.	0.9	18
245	A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). <i>Blood</i> , 2007, 109, 5527-5527.	0.6	26
246	IVIg in ITP: no role for cytokines?. <i>Blood</i> , 2007, 109, 4-5.	0.6	1
247	Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). <i>Blood</i> , 2007, 110, 3526-3531.	0.6	88
248	New therapies for immune thrombocytopenic purpura. <i>Current Opinion in Hematology</i> , 2007, 14, 427-431.	1.2	12
249	Immune thrombocytopenic purpura in adults. <i>Current Opinion in Hematology</i> , 2007, 14, 535-556.	1.2	77
250	Antepartum Treatment Without Early Cordocentesis for Standard-Risk Alloimmune Thrombocytopenia. <i>Obstetrics and Gynecology</i> , 2007, 110, 249-255.	1.2	73
251	Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , 2007, 357, 2237-2247.	13.9	718
252	Immune Thrombocytopenic Purpura. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 743-759.	0.9	64

#	ARTICLE	IF	CITATIONS
253	A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: Its development and validation. <i>Health and Quality of Life Outcomes</i> , 2007, 5, 11.	1.0	54
254	Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: Clinical and immunologic outcomes in heterozygotes. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 1178-1185.	1.5	158
255	Immune Thrombocytopenic Purpura. , 2007, , 831-845.		2
256	Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: Results of a small, randomized prospective comparison. <i>American Journal of Hematology</i> , 2007, 82, 335-341.	2.0	13
257	Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2007, 82, 192-198.	2.0	11
258	Advances in the management of alloimmune thrombocytopenia. <i>British Journal of Haematology</i> , 2007, 136, 366-378.	1.2	66
259	The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. <i>British Journal of Haematology</i> , 2007, 138, 245-248.	1.2	140
260	Identifying babies with neonatal alloimmune thrombocytopenia and the responsible antigens. <i>Transfusion</i> , 2007, 47, 6-7.	0.8	4
261	R935788: A Phase II, Single Center, Open Label, Efficacy and Safety, Ascending Dose, Pilot Study for the Treatment of Adult Immune Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2007, 110, 1310-1310.	0.6	2
262	Evaluation of AMG 531 Efficacy in Nonsplenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study.. <i>Blood</i> , 2007, 110, 565-565.	0.6	5
263	Defective Circulating CD25 Regulatory T Cells in Patients with Chronic Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2007, 110, 570-570.	0.6	1
264	Novel thrombopoietic agents: preliminary activity, potential benefit. <i>The Journal of Supportive Oncology</i> , 2007, 5, 63-84.	2.3	2
265	AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP. <i>New England Journal of Medicine</i> , 2006, 355, 1672-1681.	13.9	489
266	Treatment of Immune Thrombocytopenic Purpura in Adults. <i>Seminars in Hematology</i> , 2006, 43, S3-S10.	1.8	48
267	Review of Therapies for Immune Thrombocytopenic Purpura. <i>Seminars in Hematology</i> , 2006, 43, S1-S2.	1.8	1
268	When are platelets just platelets?. <i>Blood</i> , 2006, 107, 3426-3427.	0.6	1
269	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. <i>Blood</i> , 2006, 107, 2639-2642.	0.6	204
270	Parallel Randomized Trials of Risk-Based Therapy for Fetal Alloimmune Thrombocytopenia. <i>Obstetrics and Gynecology</i> , 2006, 107, 91-96.	1.2	165

#	ARTICLE	IF	CITATIONS
271	The pathogenesis of immune thrombocytopaenic purpura. British Journal of Haematology, 2006, 133, 364-374.	1.2	238
272	Alloimmune thrombocytopenia: State of the art 2006. American Journal of Obstetrics and Gynecology, 2006, 195, 907-913.	0.7	57
273	Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. American Journal of Hematology, 2006, 81, 19-25.	2.0	84
274	Long-Term Effects of Fetal and Neonatal Alloimmune Thrombocytopenia and Its Antenatal Treatment on the Medical and Developmental Outcomes of Affected Children. American Journal of Perinatology, 2006, 23, 487-492.	0.6	34
275	Insights into Therapeutic Mechanisms: Measuring Immature Platelet Fraction (IPF) Describes Response to Treatment in Immune Thrombocytopenic Purpura (ITP).. Blood, 2006, 108, 1070-1070.	0.6	4
276	GMA161 Treatment of Refractory ITP: Efficacy of Fc γ 3-R111 Blockade.. Blood, 2006, 108, 1074-1074.	0.6	5
277	Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.. Blood, 2006, 108, 475-475.	0.6	16
278	Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.. Blood, 2006, 108, 476-476.	0.6	18
279	Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year.. Blood, 2006, 108, 479-479.	0.6	17
280	Velocardiofacial Syndrome (VCF): Presentation with and Management of Immune Cytopenias.. Blood, 2006, 108, 3986-3986.	0.6	0
281	Development and Initial Validation of the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire (ITP-PAQ), a Disease-Specific Health-Related Quality of Life (HRQoL) Questionnaire.. Blood, 2006, 108, 1078-1078.	0.6	0
282	How I treat idiopathic thrombocytopenic purpura (ITP). Blood, 2005, 106, 2244-2251.	0.6	320
283	Fetal and neonatal alloimmune thrombocytopenia in pregnancies involving in vitro fertilization: A report of four cases. American Journal of Obstetrics and Gynecology, 2005, 192, 543-547.	0.7	23
284	Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatric Blood and Cancer, 2005, 45, 176-183.	0.8	111
285	Chronic immune thrombocytopenic purpura in children: Assessment of rituximab treatment. Journal of Pediatrics, 2005, 146, 217-221.	0.9	127
286	Response to Treatment of Helicobacter Pylori in Patients with Immune Thrombocytopenic Purpura: A Systematic Review and Metaanalysis.. Blood, 2005, 106, 2151-2151.	0.6	2
287	Re-Treatment with Rituximab in ITP: Comparison of Standard Dose with 2 Forms of Augmented Rituximab.. Blood, 2005, 106, 1237-1237.	0.6	1
288	Assessment of Bleeding in Thrombocytopenic Patients (pts) with Immune Thrombocytopenic Purpura (ITP).. Blood, 2005, 106, 1255-1255.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura. <i>Haematologica</i> , 2005, 90, 1715-6.	1.7	8
290	Congenital and Acquired Thrombocytopenia. Hematology American Society of Hematology Education Program, 2004, 2004, 390-406.	0.9	76
291	Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by Fc γ 3 RIIa and Fc γ 3 RIIIa polymorphisms. <i>British Journal of Haematology</i> , 2004, 124, 511-518.	1.2	88
292	The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2004, 125, 232-239.	1.2	289
293	Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. <i>American Journal of Hematology</i> , 2004, 76, 205-213.	2.0	197
294	Differential diagnosis and management of thrombocytopenia in childhood. <i>Pediatric Clinics of North America</i> , 2004, 51, 1109-1140.	0.9	26
295	IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. <i>Thrombosis and Haemostasis</i> , 2004, 91, 771-778.	1.8	51
296	Does <i>Helicobacter pylori</i> initiate or perpetuate immune thrombocytopenic purpura?. <i>Blood</i> , 2004, 103, 890-896.	0.6	153
297	Splenectomized Patients Have Reduced CD27+ Memory B Cells but Protective Antibody Responses to Pneumococcal Vaccination.. <i>Blood</i> , 2004, 104, 3025-3025.	0.6	1
298	Intravenous Immunoglobulin Manufactured Using a Novel Caprylate and Chromatography-Based Method (IGIV-C, Gamunex $\text{\textcircled{R}}$) Was Safe and Well Tolerated When Administered at an Increased Maximum Rate in Patients with Idiopathic Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2004, 104, 3027-3027.	0.6	2
299	Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). <i>American Journal of Hematology</i> , 2003, 72, 94-98.	2.0	151
300	Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. <i>British Journal of Haematology</i> , 2003, 123, 142-146.	1.2	72
301	Fetal and Neonatal Cytopenias: What Have We Learned?. <i>American Journal of Perinatology</i> , 2003, 20, 425-432.	0.6	8
302	Intracranial Hemorrhage in Immune Thrombocytopenic Purpura: A Retrospective Analysis. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 660-664.	0.3	127
303	Development of Disease-Specific Health-Related Quality-of-Life Instruments for Children With Immune Thrombocytopenic Purpura and Their Parents. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 56-62.	0.3	51
304	Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?. <i>Blood</i> , 2002, 99, 1922-1927.	0.6	84
305	Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. <i>Blood</i> , 2002, 100, 1388-1398.	0.6	132
306	High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2002, 118, 836-838.	1.2	20

#	ARTICLE	IF	CITATIONS
307	Alloimmune thrombocytopenia. , 2002, , 569-583.		0
308	Another interaction of the FcR system with IVIG. Thrombosis and Haemostasis, 2002, 88, 890-1.	1.8	7
309	Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. Journal of Pediatrics, 2001, 138, 862-867.	0.9	84
310	Thrombocytopenia. , 2001, , 155-185.		0
311	A dose of 75â€¹¼g/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50â€¹¼g/kg/d in adults with immune thrombocytopenic purpura. British Journal of Haematology, 2001, 112, 1076-1078.	1.2	118
312	A pilot study of rhull-11 treatment of refractory ITP. American Journal of Hematology, 2001, 66, 172-177.	2.0	54
313	Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy?. American Journal of Hematology, 2001, 67, 27-33.	2.0	44
314	Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. American Journal of Obstetrics and Gynecology, 2001, 185, 976-980.	0.7	39
315	Alloimmune Thrombocytopenia in the Fetus and Newborn. Seminars in Thrombosis and Hemostasis, 2001, 27, 245-252.	1.5	55
316	Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders. Hematology American Society of Hematology Education Program, 2001, 2001, 282-305.	0.9	68
317	A pilot study of rhull-11 treatment of refractory ITP. , 2001, 66, 172.		3
318	Th1 and Th2 cytokines in a patient with Evans' syndrome and profound lymphopenia. British Journal of Haematology, 2000, 110, 968-970.	1.2	24
319	Fc receptor blockade and immune thrombocytopenic purpura. Seminars in Hematology, 2000, 37, 261-266.	1.8	78
320	Splenectomy-sparing strategies for the treatment and long-term maintenance of chronic idiopathic (immune) thrombocytopenic purpura. Seminars in Hematology, 2000, 37, 1-4.	1.8	16
321	THROMBOCYTOPENIA WITH ABSENT RADII: Frequency of Marrow Megakaryocyte Progenitors, Proliferative Characteristics, and Megakaryocyte Growth and Development Factor Responsiveness. Pediatric Hematology and Oncology, 2000, 17, 299-306.	0.3	18
322	Fc receptor blockade and immune thrombocytopenic purpura. Seminars in Hematology, 2000, 37, 261-266.	1.8	61
323	Hematologic Toxicity of Sodium Valproate. The American Journal of Pediatric Hematology/oncology, 2000, 22, 62-65.	1.3	182
324	The Treatment of Patients with Autoimmune Thrombocytopenia with Intravenous IgG-Anti-D. Vox Sanguinis, 1999, 76, 252-252.	0.7	0

#	ARTICLE	IF	CITATIONS
325	Is it necessary to test patients with immune thrombocytopenic purpura (ITP) for seropositivity to HTLV-1?. , 1999, 61, 94-97.		4
326	Alloimmune Thrombocytopenia. Clinical Obstetrics and Gynecology, 1999, 42, 335-348.	0.6	19
327	9 The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. Best Practice and Research: Clinical Haematology, 1998, 11, 391-408.	1.1	33
328	Fetal Alloimmune Thrombocytopenia. New England Journal of Medicine, 1997, 337, 22-26.	13.9	262
329	Intravenous Anti-D Treatment of Immune Thrombocytopenic Purpura: Experience in 272 Patients. Blood, 1997, 89, 2689-2700.	0.6	299
330	Antiplatelet antibody testing in thrombocytopenic pregnant women. American Journal of Obstetrics and Gynecology, 1996, 174, 1014-1018.	0.7	67
331	Antenatal management of alloimmune thrombocytopenia with intravenous \hat{I}^3 -globulin: A randomized trial of the addition of low-dose steroid to intravenous \hat{I}^3 -globulin. American Journal of Obstetrics and Gynecology, 1996, 174, 1414-1423.	0.7	204
332	Serum levels of GM \hat{A} CSF are elevated in patients with thrombocytopenia. British Journal of Haematology, 1996, 92, 486-488.	1.2	20
333	Evans Syndrome. Journal of Pediatric Hematology/Oncology, 1995, 17, 290-295.	0.3	53
334	Alloimmune thrombocytopenia: Fetal and neonatal losses related to cordocentesis. American Journal of Obstetrics and Gynecology, 1995, 172, 475-479.	0.7	169
335	Accurate Intrapartum Estimation of Fetal Platelet Count by Fetal Scalp Sample Smear. American Journal of Perinatology, 1994, 11, 42-45.	0.6	18
336	Favorable Neurological Outcome in 7 Cases of Perinatal Intracranial Hemorrhage Due to Immune Thrombocytopenia. Journal of Pediatric Hematology/Oncology, 1991, 13, 156-159.	0.3	19
337	Estimation of the Risk of Thrombocytopenia in the Offspring of Pregnant Women with Presumed Immune Thrombocytopenic Purpura. New England Journal of Medicine, 1990, 323, 229-235.	13.9	215
338	Isolated thrombocytopenia in patients infected with HIV: Treatment with intravenous gammaglobulin. American Journal of Hematology, 1988, 28, 79-84.	2.0	45
339	Thein utero diagnosis and management of alloimmune thrombocytopenia. Prenatal Diagnosis, 1988, 8, 329-331.	1.1	23
340	Antenatal Treatment of Neonatal Alloimmune Thrombocytopenia. New England Journal of Medicine, 1988, 319, 1374-1378.	13.9	320
341	Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fc \hat{I}^3 -Receptor Antibody. New England Journal of Medicine, 1986, 314, 1236-1239.	13.9	360
342	Therapy in Cytopenia. Vox Sanguinis, 1986, 51, 69-73.	0.7	9

#	ARTICLE	IF	CITATIONS
343	Intravenous Immune Serum Globulin in Immune Thrombocytopenia: Clinical Results and Biochemical Evaluation. <i>Vox Sanguinis</i> , 1985, 49, 44-50.	0.7	19
344	A heparin-like anticoagulant in an 8-month-old boy with acute monoblastic leukemia. <i>American Journal of Hematology</i> , 1984, 16, 83-90.	2.0	52
345	Intravenous use of gammaglobulin in the treatment of chronic immune thrombocytopenic purpura as a means to defer splenectomy. <i>Journal of Pediatrics</i> , 1983, 103, 651-654.	0.9	107
346	Fetal and neonatal immune thrombocytopenia. , 0 , 141-156.		0